You have a lot to protect, bank more than cord blood.

What is Placental & Cord Blood Banking?

LifebankUSA collects stem cells from 2 prenatal sources of stem cell-rich blood: the umbilical cord and the placenta. Stem cells collected from both sources have been used for transplants, and only LifebankUSA is registered with the FDA for both products.

Compared to cord blood banking alone, Placental & Cord Blood Banking yields 39% more of a particular type of cell called a CD34+ stem cell.1 Studies have shown that using more CD34+ stem cells can lead to a significant survival advantage in transplant patients.2,3 Please click here for more information on CD34+ cells.

Placental and cord blood also contain mesenchymal* - like cells,4 which may prove valuable in new treatments that may emerge.4-7 Please click here for more information on mesenchymal-like stem cells.
†† Data on file.

"LifebankUSA is a pioneer in placenta-stem cell technology. Our stem cell banking program meets and exceeds the highest standards in the industry-and we are the only company that can provide access to technology that allows you to boost the number of cells you can recover after birth."
- Robert Hariri, MD, PhD
CEO and Founder of LifebankUSA

Dr. Robert Hariri, CEO and founder of LifebankUSA, was awarded his MD and PhD degrees from Cornell University Medical College, New York, NY, and received his surgical training at New York Hospital-Cornell Medical Center. Dr. Hariri has been extensively published in leading medical and scientific publications. In 2006, he was awarded the Thomas Alva Edison Patent Award for his achievements related to placental stem cell collection.
"For cancer patients, stem cells are used to help restore the immune system. They fight the disease and also replace normal blood cells killed by heavy doses of chemotherapy. For patients with weakened immune systems, healthy cord blood helps create the infection-fighting cells they lack."
- Dr. Bernadine Healy, CBS This Morning

Stem cells from placental and cord blood are indicated to rebuild blood. View Product Information.

Cord blood and placenta-derived stem cells banked with LifebankUSA are indicated for hematopoietic reconstitution (the reformation of blood cellular components) for autologous use or use in first or second degree blood relatives. Any use of cord blood and placental stem cells other than for hematopoietic reconstitution is considered investigational, including regenerative medicine* therapies.

The chance that a child will use his/her own stored stem cells during his/her lifetime for currently treated conditions is estimated at 1 in 400.† These odds may increase if there is a family history of certain blood disorders or cancers. The potential risks and benefits of stem cell transplantation vary and depend on many factors, such as the amount and quality of the stem cells collected, the HLA compatibility between recipient and donor, and the client's overall health. Talk with your health care provider. For more information, call us at 1-877-LIFEBANKUSA ( 1-877-543-3226 ).

*These uses are not consistent with current labeling, are investigational and may never become standard therapy.
† Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MM. Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. Biol Blood Marrow Transplant. 2008;14(3):316-322.

References:
  1. Data on file A, LifebankUSA; 2010.
  2. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100(5):1611-1618.
  3. Styczynski J, Cheung Y-K, Garvin J, et al. Unrelated donor transplants: outcomes of unrelated cord blood transplantation in pediatric recipients. Bone Marrow Transplant. 2004;34(2):129-136.
  4. Harris DT. Non-haematological uses of cord blood stem cells. Br J Haematol. 2009;147(2):177-184.
  5. Richardson SM, Hoyland JA, Mobasheri R, Csaki C, Shakibaei M, Mobasheri A. Mesenchymal stem cells in regenerative medicine: opportunities and challenges for articular cartilage and intervertebral disc tissue engineering. J Cell Physiol. 2010;222(1):23-32.
  6. Yen BL, Huang H-I, Chien C-C, et al. Isolation of multipotent cells from human term placenta. Stem Cells. 2005;23(1):3-9.
  7. Undale AH, Westendorf JJ, Yaszemski MJ, Khosla S. Mesenchymal Stem Cells for Bone Repair and Metabolic Bone Diseases. Mayo Clin Proc. 2009;84(10):893-902.